BR1321a : Breast cancer tissue array with lymph node metastasis (LN+) and non-lymph node metastatic (LN-), including pathology grade, TNM, clinical stage and IHC results (ER/PR/HER2/Ki-67),120 cases/132 cores, replacing BR1321
  • $474.00
  • Unstained
  • H&E
-+
Microarray Panel Breast invasive carcinoma of no special type tissue microarray with adjacent normal tissue, containing 60 cases of lymph node metastasis (LN+), 50 No lymph node metastatic (LN-), 1 normal breast tissue, plus 9 adjacent normal tissue, triplicate cores of lymph node positive (LN+) from 1-3 cases, single core of the last 57 cases of lymph node positive (LN+), triplicate cores of lymph node positive (LN-) from 1-3 cases, single core of the last 47 cases of lymph node positive (LN-), single core normal and adjacnet normal bresat tissue
Cores 132
TissueArray.Com Tissue Array BR1321a
Cases 120
Row number 12
Column number 11
Core Diameter (mm) 1
Thickness (µm) 5
Tissue Array Type FFPE
Species Human
Applications 54
Notes 1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours.
In the following specsheet,“*” means invalid core; “-” means no applicable or negative in IHC markers.
Mouseover and click individual cores to view high resolution images.
Slide Label: TissueArray.Com Tissue Array
1234567891011 
ABreBreBreBreBreBreBreBreBreBreBre 
BBreBreBreBreBreBreBreBreBreBreBre 
CBreBreBreBreBreBreBreBreBreBreBre 
DBreBreBreBreBreBreBreBreBreBreBre 
EBreBreBreBreBreBreBreBreBreBreBre 
FBreBreBreBreBreBreBreBreBreBreBre 
GBreBreBreBreBreBreBreBreBreBreBre 
HBreBreBreBreBreBreBreBreBreBreBre 
IBreBreBreBreBreBreBreBreBreBreBre 
JBreBreBreBreBreBreBreBreBreBreBre 
KBreBreBreBreBreBreBreBreBreBreBre 
LBreBreBreBreBreBreBreBreBreBreBreMarked point
Legend: Bre - Breast

- Malignant tumor, - Malignant tumor (stage I), - Malignant tumor (stage IIA), - Malignant tumor (stage IIB), - Malignant tumor (stage IIIA), - Malignant tumor (stage IIIB), - Malignant tumor (stage IV), - NAT, - Normal tissue

Specification Sheet (Sortable), tissue IDs are available in exported Excel files.
Pos.
No.
Age
Sex
Organ/Anatomic Site
Pathology diagnosis
TNM
Grade
Stage
Type
ER
PR
HER2
Ki67
Image
A1
1
54
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
1
IIB
Malignant
+++,100%
+++,90%
2+
+,10%
A2
2
54
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
1
IIB
Malignant
+++,100%
+++,100%
2+
+,10%
A3
3
54
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
1
IIB
Malignant
+++,100%
+++,100%
2+
+,5%
A4
4
49
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
1
IIB
Malignant
-
-
3+
+,15%
A5
5
49
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
1
IIB
Malignant
-
-
3+
+,20%
A6
6
49
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
1
IIB
Malignant
-
-
3+
+,2%
A7
7
44
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
1
IIB
Malignant
+++,100%
+++,90%
1+
+,10%
A8
8
44
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
1
IIB
Malignant
+++,100%
+++,90%
1+
+,10%
A9
9
44
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
1
IIB
Malignant
+++,100%
+++,100%
1+
+,15%
A10
10
40
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
1
IIB
Malignant
+,10%
+,15%
1+
+,5%
A11
11
78
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
2
IIB
Malignant
+++,90%
-
2+
+,20%
B1
12
50
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
2
IIB
Malignant
+++,90%
++,30%
3+
+,40%
B2
13
53
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
2
IIB
Malignant
-
-
3+
+,60%
B3
14
39
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
2
IIB
Malignant
++,70%
-
2+
+,15%
B4
15
41
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
2
IIB
Malignant
+++,80%
++,60%
2+
+,15%
B5
16
45
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
2
IIB
Malignant
+++,100%
+,50%
1+
+,10%
B6
17
45
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
2
IIB
Malignant
+++,90%
+,60%
3+
+,20%
B7
18
39
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
2
IIB
Malignant
++,80%
+,10%
3+
+,15%
B8
19
52
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
2
IIB
Malignant
-
-
2+
+,35%
B9
20
70
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
2
IIB
Malignant
-
-
3+
+,20%
B10
21
60
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
2
IIB
Malignant
+++,90%
+++,80%
0
+,20%
B11
22
45
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
2
IIB
Malignant
+,5%
-
3+
+,15%
C1
23
42
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
1
IIB
Malignant
+,60%
-
3+
-
C2
24
53
F
Breast
Invasive carcinoma of no special type,LN+
T1N1M0
2
IIA
Malignant
+,40%
-
3+
+,10%
C3
25
58
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
2
IIB
Malignant
+++,100%
+++,100%
1+
+,15%
C4
26
79
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
2
IIB
Malignant
++,70%
-
0
-
C5
27
45
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
2
IIB
Malignant
++,90%
++,80%
2+
+,10%
C6
28
52
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
2
IIB
Malignant
+,40%
-
0
-
C7
29
48
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
2
IIB
Malignant
+++,70%
++,20%
1+
+,20%
C8
30
62
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
2
IIB
Malignant
-
-
2+
-
C9
31
54
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
2
IIB
Malignant
+++,90%
+,10%
2+
+,10%
C10
32
57
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
2
IIB
Malignant
-
-
2+
+,30%
C11
33
66
F
Breast
Invasive carcinoma of no special type,LN+
T1N1M0
2
IIA
Malignant
+,20%
-
3+
+,25%
D1
34
44
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
3
IIB
Malignant
-
-
3+
-
D2
35
42
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
3
IIB
Malignant
-
-
3+
-
D3
36
43
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
3
IIB
Malignant
+,5%
+,5%
0
-
D4
37
60
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
3
IIB
Malignant
+++,100%
+++,90%
0
-
D5
38
78
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
3
IIB
Malignant
+,15%
-
0
-
D6
39
65
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
3
IIB
Malignant
-
-
3+
-
D7
40
51
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
3
IIB
Malignant
++,60%
++,50%
3+
+,50%
D8
41
39
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
3
IIB
Malignant
+++,80%
++,60%
2+
+,30%
D9
42
42
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
3
IIB
Malignant
-
-
0
-
D10
43
56
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
3
IIB
Malignant
++,45%
-
0
+,2%
D11
44
41
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
3
IIB
Malignant
-
-
0
+,15%
E1
45
43
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
3
IIB
Malignant
-
-
1+
+,70%
E2
46
39
F
Breast
Invasive carcinoma of no special type,LN+
T2N1M0
3
IIB
Malignant
-
-
0
+,80%
E3
47
44
F
Breast
Invasive carcinoma of no special type,LN+
T2N2M0
1
IIIA
Malignant
+++,100%
+++,90%
0
+,15%
E4
48
80
F
Breast
Invasive carcinoma of no special type,LN+
T2N2M0
1
IIIA
Malignant
-
-
3+
+,15%
E5
49
48
F
Breast
Invasive carcinoma of no special type,LN+
T3N1M0
3
IIIA
Malignant
*
-
2+
+,2%
E6
50
48
F
Breast
Invasive carcinoma of no special type,LN+
T3N1M0
3
IIIA
Malignant
-
-
3+
+,10%
E7
51
28
F
Breast
Invasive carcinoma of no special type,LN+
T2N2M0
3
IIIA
Malignant
++,80%
+++,25%
1+
+,15%
E8
52
40
F
Breast
Invasive carcinoma of no special type,LN+
T2N2M0
1
IIIA
Malignant
-
-
3+
+,20%
E9
53
58
F
Breast
Invasive carcinoma of no special type,LN+
T3N2M0
3
IIIA
Malignant
+++,100%
-
1+
+,25%
E10
54
78
F
Breast
Invasive carcinoma of no special type,LN+
T4N1M0
3
IIIB
Malignant
-
-
2+
-
E11
55
59
F
Breast
Invasive carcinoma of no special type,LN+
T2N2M0
-
IIIA
Malignant
+,20%
+,5%
3+
+,30%
F1
56
53
F
Breast
Invasive carcinoma of no special type,LN+
T4N2M0
3
IIIB
Malignant
-
-
1+
+,2%
F2
57
46
F
Breast
Invasive carcinoma of no special type,LN+
T4N2M1
3
IV
Malignant
+++,100%
+++,30%
1+
+,20%
F3
58
68
F
Breast
Invasive carcinoma of no special type,LN+
T4N2M1
3
IV
Malignant
++,30%
+,15%
3+
-
F4
59
33
F
Breast
Invasive carcinoma of no special type,LN+
T4N2M1
3
IV
Malignant
+++,80%
++,80%
3+
+,40%
F5
60
70
F
Breast
Invasive carcinoma of no special type,LN+
T4N2M1
3
IV
Malignant
++,50%
-
2+
-
F6
61
50
F
Breast
Invasive carcinoma of no special type,LN+
T4N3M1
3
IV
Malignant
++,70%
++,70%
2+
+,30%
F7
62
73
F
Breast
Invasive carcinoma of no special type,LN+
T4N1M1
3
IV
Malignant
+++,90%
++,20%
3+
+,70%
F8
63
40
F
Breast
Invasive carcinoma of no special type,LN+
T2N0M1
3
IV
Malignant
-
-
0
+,45%
F9
64
54
F
Breast
Invasive carcinoma of no special type,LN+
T3N1M1
2
IV
Malignant
-
-
3+
+,5%
F10
65
50
F
Breast
Mucinous carcinoma,LN+
T4N1M1
1
IV
Malignant
+++,90%
+,8%
3+
+,20%
F11
66
45
F
Breast
Mucinous carcinoma,LN+
T2N1M1
2
IV
Malignant
*
*
*
*
G1
67
44
F
Breast
Invasive carcinoma of no special type,LN-
T1N0M0
3
I
Malignant
+++,100%
+++,90%
2+
-
G2
68
44
F
Breast
Invasive carcinoma of no special type,LN-
T1N0M0
3
I
Malignant
+++,100%
+++,90%
2+
-
G3
69
44
F
Breast
Invasive carcinoma of no special type,LN-
T1N0M0
3
I
Malignant
+++,100%
+++,100%
2+
+,2%
G4
70
50
F
Breast
Invasive carcinoma of no special type,LN-
T1N0M0
2
I
Malignant
-
-
0
-
G5
71
50
F
Breast
Invasive carcinoma of no special type,LN-
T1N0M0
2
I
Malignant
*
*
*
*
G6
72
50
F
Breast
Invasive carcinoma of no special type,LN-
T1N0M0
2
I
Malignant
-
-
0
-
G7
73
65
F
Breast
Invasive carcinoma of no special type,LN-
T1N0M0
2
I
Malignant
+++,100%
-
3+
+,20%
G8
74
65
F
Breast
Invasive carcinoma of no special type,LN-
T1N0M0
2
I
Malignant
+++,100%
-
2+
+,15%
G9
75
65
F
Breast
Invasive carcinoma of no special type,LN-
T1N0M0
2
I
Malignant
+++,100%
+,5%
2+
+,15%
G10
76
54
F
Breast
Invasive carcinoma of no special type,LN-
T1N0M0
2
I
Malignant
+++,90%
+++,50%
3+
+,60%
G11
77
70
F
Breast
Invasive carcinoma of no special type,LN-
T1N0M0
2
I
Malignant
+++,100%
+++,100%
2+
+,15%
H1
78
35
F
Breast
Invasive carcinoma of no special type,LN-
T1N0M0
3
I
Malignant
*
*
*
*
H2
79
45
F
Breast
Invasive carcinoma of no special type,LN-
T1N0M0
3
I
Malignant
-
-
1+
+,20%
H3
80
32
F
Breast
Invasive carcinoma of no special type,LN-
T1N0M0
3
I
Malignant
-
-
3+
+,35%
H4
81
57
F
Breast
Invasive carcinoma of no special type,LN-
T1N0M0
3
I
Malignant
-
-
0
+,30%
H5
82
47
F
Breast
Invasive carcinoma of no special type,LN-
T1N0M0
3
I
Malignant
-
-
3+
+,5%
H6
83
62
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
+,65%
-
3+
+,60%
H7
84
43
F
Breast
Invasive carcinoma of no special type,LN-
T3N0M0
3
IIB
Malignant
-
-
0
-
H8
85
47
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
-
+,5%
2+
-
H9
86
63
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
+++,100%
+++,100%
1+
+,30%
H10
87
46
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
+++,100%
+,5%
1+
+,50%
H11
88
47
F
Breast
Invasive lobular carcinoma,LN-
T2N0M0
-
IIA
Malignant
+++,100%
-
1+
+,10%
I1
89
41
F
Breast
Invasive carcinoma of no special type,LN-
T3N0M0
3
IIB
Malignant
*
-
0
+,50%
I2
90
52
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
-
IIA
Malignant
*
*
*
*
I3
91
52
F
Breast
Invasive carcinoma of no special type,LN-
T3N0M0
2
IIB
Malignant
+,10%
-
3+
+,40%
I4
92
50
F
Breast
Invasive carcinoma of no special type,LN-
T3N0M0
3
IIB
Malignant
+,10%
-
3+
+,20%
I5
93
54
F
Breast
Invasive carcinoma of no special type,LN-
T3N0M0
3
IIB
Malignant
+++,100%
+++,10%
2+
+,10%
I6
94
53
F
Breast
Invasive carcinoma of no special type,LN-
T3N0M0
3
IIB
Malignant
-
-
0
-
I7
95
47
F
Breast
Invasive carcinoma of no special type,LN-
T3N0M0
3
IIB
Malignant
-
-
1+
+,25%
I8
96
67
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
2
IIA
Malignant
+++,100%
+++,90%
0
+,5%
I9
97
39
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
2
IIA
Malignant
-
-
3+
+,40%
I10
98
60
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
-
-
2+
+,80%
I11
99
40
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
+,10%
-
3+
+,65%
J1
100
65
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
++,70%
+,10%
0
-
J2
101
47
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
+,10%
-
3+
+,20%
J3
102
64
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
+++,70%
+++,60%
2+
+,30%
J4
103
64
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
+++,70%
-
2+
+,15%
J5
104
30
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
+++,90%
+,10%
1+
+,55%
J6
105
38
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
*
IIA
Malignant
*
*
*
*
J7
106
66
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
+++,80%
++,60%
2+
+,10%
J8
107
49
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
+++,80%
+++,90%
3+
+,20%
J9
108
37
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
+++,100%
+++,90%
2+
+,20%
J10
109
48
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
-
-
2+
+,30%
J11
110
47
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
-
+++,70%
1+
+,35%
K1
111
51
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
-
-
3+
+,20%
K2
112
51
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
-
-
3+
+,15%
K3
113
66
F
Breast
Invasive carcinoma of no special type,LN-
T2N2M0
-
IIIA
Malignant
-
-
3+
-
K4
114
47
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
+++,100%
+++,80%
2+
-
K5
115
49
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
-
-
3+
+,25%
K6
116
45
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
+,15%
+++,90%
2+
-
K7
117
46
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
+++,100%
+,5%
2+
+,20%
K8
118
46
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
+,5%
-
3+
+,25%
K9
119
42
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
*
*
*
*
K10
120
60
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
+++,80%
+++,80%
3+
+,30%
K11
121
40
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
3
IIA
Malignant
++,70%
++,40%
3+
+,35%
L1
122
66
F
Breast
Invasive carcinoma of no special type,LN-
T2N0M0
-
IIA
Malignant
-
-
1+
+,15%
L2
123
50
F
Breast
Bresat tissue
-
-
-
Normal
*
*
*
*
L3
124
40
F
Breast
Adjacent normal breast tissue
-
-
-
NAT
++
++
0
-
L4
125
51
F
Breast
Adjacent normal breast tissue
-
-
-
NAT
*
*
*
*
L5
126
44
F
Breast
Adjacent normal breast tissue
-
-
-
NAT
*
*
*
*
L6
127
35
F
Breast
Adjacent normal breast tissue
-
-
-
NAT
+
-
0
-
L7
128
38
F
Breast
Adjacent normal breast tissue
-
-
-
NAT
+
+
0
-
L8
129
44
F
Breast
Adjacent normal breast tissue
-
-
-
NAT
++
++
0
-
L9
130
47
F
Breast
Adjacent normal breast tissue
-
-
-
NAT
+
+
0
-
L10
131
52
F
Breast
Adjacent normal breast tissue
-
-
-
NAT
*
*
*
*
L11
132
43
F
Breast
Adjacent normal breast tissue
-
-
-
NAT
*
*
*
*
-
0
42
M
Adrenal gland
Pheochromocytoma (tissue marker)
-
Malignant
Find overlapping cases with this tissue array:
 

Write a review

Please login or register to review
 
  • Product Code: BR1321a
  • Availability: In Stock

Tags: With normal control, Stage (TNM), Triplicate cores per case, With normal control (), Single core per case